Abstract: One aspect of the present invention relates to a method of inhibiting growth of Listeria monocytogenes on or in a product by applying an inhibitor compound of the formula: where the dashed lines are optional and represent a double bond or triple bond, and at least one of the dashed lines is present. Also disclosed is a method of inhibiting growth of Listeria monocytogenes on or in a subject by treating the subject with that compound. Further aspects of the present invention relate to pharmaceutical compositions, food product compositions, personal care product compositions, and cleaning product compositions comprising the subject inhibitor compounds.

Abstract: One aspect of the present invention relates to a method of inhibiting growth of Listeria monocytogenes on or in a product by applying an inhibitor compound of the formula: where the dashed lines are optional and represent a double bond or triple bond, and at least one of the dashed lines is present. Also disclosed is a method of inhibiting growth of Listeria monocytogenes on or in a subject by treating the subject with that compound. Further aspects of the present invention relate to pharmaceutical compositions, food product compositions, personal care product compositions, and cleaning product compositions comprising the subject inhibitor compounds.

Abstract: The present invention relates to a dosage form which comprises amorphous calcium L-5-methylfolate and cysteine as stabilizing agent and optionally, further auxiliary agents. The dosage forms according to the invention resolves the problem of instability of amorphous calcium L-5-methylfolate to the oxidation by air.

Abstract: The present invention relates to a compound material consisting of a natural zeolite having calcium as an exchangeable cation, in which hydroxyapatite on a nanometric scale is grown in a controlled manner on the surface thereof; to the method by which said compound material is obtained; and to the use thereof for removing fluoride from water in order to make same drinkable. As a result of the aforementioned special characteristics of hydroxyapatite crystals, said material has a very high intrinsic capacity (based on the weight of hydroxyapatite) for removing fluoride. This capacity, combined with the low cost and ease of access to the materials used for preparing same, and with the straightforward nature of the method, means that said material is the perfect candidate for removing fluoride from water having high levels of this contaminant.

Abstract: The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogs thereof and the manufacturing process of such pharmaceutical compositions.

Abstract: The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogues thereof and the manufacturing process of such pharmaceutical compositions.

Abstract: The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogues thereof and the manufacturing process of such pharmaceutical compositions.

Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Abstract: The present invention provides the use of a compound of formula (I); wherein: n is 0, 1, 2, or 3, the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds; R, and R?are independently selected from hydrogen, alkyl, aryl, —OH, —OR? —SH, —SR?—NH, —NHR?, ?O, ?NH, ?NR?; R? is independently selected from alkyl, aryl, in the preparation of a medicament for the treatment of a disease requiring a GSK-3 inhibitor. Also provided is a compound of formula (II); wherein n is 0, 1, 2, or 3 the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds. Also provided are methods of treating chronic neurodegenerative conditions.

Abstract: A family of compounds of formula (I) wherein: X is one of the following radicals: which behaves as dual site acetyl-cholinesterase inhibitors and which are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerst-mann-Straussler-Scheiner disease.

Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.

Abstract: The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the ?-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.

Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Abstract: A method and apparatus for measuring the rheological properties of a polymer melt includes flowing the polymer melt from a first reactor to a device through a conduit at a predetermined flow rate, measuring a first pressure of the polymer melt at a first location in the conduit, measuring a second pressure at a second location downstream from the first location, measuring a temperature at a third location in the conduit, wherein the third location is between the first location and the second location, and calculating the rheological property of the polymer melt as it flows through the conduit. The method and apparatus do not require diversion of the polymer melt from the main process stream.

Abstract: A method and apparatus for measuring the rheological properties of a polymer melt includes flowing the polymer melt from a first reactor to a device through a conduit at a predetermined flow rate, measuring a first pressure of the polymer melt at a first location in the conduit, measuring a second pressure at a second location downstream from the first location, measuring a temperature at a third location in the conduit, wherein the third location is between the first location and the second location, and calculating the Theological property of the polymer melt as it flows through the conduit. The method and apparatus do not require diversion of the polymer melt from the main process stream.